ZIM Integrated Shipping (ZIM) to be acquired by Hapag-Lloyd for $35 per share in $4.2 bln cash deal

 

 

 

 

• Chart the day before, Fri 13 Feb 2026 

 

  

Hapag-Lloyd (OTC: HPGLY) is buying Israeli competitor Zim Integrated Shipping Services for $4.2 billion as the shipping firm looks to bolster its capacity.

Germany-based Hapag-Lloyd said Monday that it signed a deal to buy Zim for $35 a share in cash, a 58% premium to Zim’s closing price of $22.20 on Friday. The total deal price of around $4.2 billion will be funded from cash reserves and external financing of up to $2.5 billion.

The combined business will have a standing capacity of more than 3 million twenty-foot equivalent units, the standard form of measurement in container shipping, and more than 400 vessels. Hapag-Lloyd currently has vessel capacity of 2.5 million TEU and 305 vessels, according to the company’s website.

The deal is expected to be completed by the end of this year, Hapag-Lloyd said. Any deal will require the consent of the state of Israel, Zim shareholders and regulators.

Zim is considered a strategic asset for the Israeli state. As part of the deal, Israel’s special stake in Zim will be transferred to a carved-out container business, which will be owned by Israeli private-equity firm FIMI, Hapag-Lloyd said. The new container line will start with 16 vessels, according to Hapag-Lloyd.

The move comes after Zim appointed an independent board that has spent the last several months conducting a strategic review to assess a range of options, including a sale of the company, capital allocation options and other measures to maximize shareholder value.

Zim recently reported a sharp drop in third-quarter earnings as freight rates tumbled and container volumes slipped, with the company warning that fourth-quarter conditions had weakened.

IPOs this week : Feb 9 - 13, 26 (wk 7)

 IPOs expected to price

• AGI (AGBK), 

• Arko Petroleum (APC), and 

• Clear Street Group (CLRS) are expected to price their IPOs and begin to trade. 

IPO lockup expirations

The IPO lockup period expires for blocks of shares of 

• Bullish (BLSH), 

• Nasus Pharma (NSRX), and 

• Magnitude International (MAGH).

== SpyGlass Pharma (SGP) began trading on the Nasdaq on Fri 6 Feb 26

 

• SpyGlass Pharma (SGP) roared onto the public markets today, as its IPO of 9.375 mln shares priced at the $16 midpoint of its $15-$17 range, opened for trading at $24 (a 50% gain), and is currently trading near $29.
• The company's lead product candidate, the Bimatoprost Drug Pad-IOL System, targets the $13 bln glaucoma market by attaching drug-eluting pads to an intraocular lens implanted during routine cataract surgery, delivering three years of medication to solve the critical issue of patient non-adherence to daily drops.
• While SGP remains pre-revenue with a net loss of $27.3 mln for the first nine months of 2025, its growth strategy relies on leveraging a known drug (bimatoprost) and a standard surgical procedure to pursue a streamlined regulatory pathway.
• Beyond its lead asset, the company is advancing a "Drug Ring System" for standalone procedures, positioning its proprietary platform as a versatile, lifetime solution for chronic eye conditions.
• The enthusiastic investor reception reflects high confidence in a technology that integrates seamlessly into the existing cataract workflow without requiring surgeons to learn complex new techniques.
• Ultimately, the market is pricing in a "de-risked" commercialization path, supported by the company's plan to utilize existing CPT reimbursement codes to align provider economics with improved patient outcomes.
• SpyGlass, based in California, is making drug-device combinations for ocular conditions. One program is a lens implanted during cataract surgery. With the help of attached drug pads, it’s meant to treat glaucoma and ocular hypertension by slowly releasing a medication that lowers eye pressure. The therapy, codenamed BIM-IOL, is currently in two Phase 3 studies that started last month. SpyGlass expects to complete enrollment in 2027.

SpyGlass Pharma is a biopharmaceutical company focused on developing sustained drug delivery systems for chronic eye diseases, particularly glaucoma. Their approach uses a proprietary non-bioerodible platform to deliver medications long-term, often integrated with existing procedures like cataract surgery.Their main drug candidates, based on their pipeline and recent clinical advancements (as of early 2026), are:

• BIM-IOL System (Bimatoprost Drug Pad-Intraocular Lens System): This is their lead product candidate. It involves proprietary non-bioerodible drug pads attached to a monofocal intraocular lens (IOL), implanted during routine cataract surgery. It delivers bimatoprost (a prostaglandin analog) sustained over up to 3 years to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
  • It is in Phase III development, with two registrational trials (SGP-005 and SGP-006) having started randomization in January 2026.
  • Earlier trials (including 36-month first-in-human data) showed positive results, such as ~37% mean IOP reduction and safety comparable to standard cataract surgery.
• BIM-DRS (Bimatoprost Drug Ring System): This is their next-generation sustained-release implant. It is a removable and replaceable ring-shaped device for multi-year drug delivery (also bimatoprost). It targets a broader glaucoma population (including those not undergoing cataract surgery) and enables retreatment for patients previously treated with the BIM-IOL System. It has potential for lifelong disease management.
  • It is earlier in development, with first-in-human studies planned for 2026.

The company's platform is designed to be flexible for other approved medications and conditions (e.g., front/back of the eye diseases), with early/preclinical mentions of potential applications like postoperative steroids, NSAIDs, chronic uveitis, or age-related macular degeneration. However, the primary focus and most advanced candidates center on the bimatoprost-based systems for glaucoma.